+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss

Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss

Gastroenterology 138(3): 896-904

Recent studies have shown an association between proton-pump inhibitor use (PPI) and hip fracture. The mechanism by which PPI use promotes the development of hip fracture is uncharacterized. Therefore, we sought to determine whether PPI use is associated with osteoporosis or accelerated bone mineral density (BMD) loss. We used the Manitoba Bone Mineral Density Database to determine the relationship between chronic PPI use and osteoporosis on an initial assessment of BMD and on BMD loss between successive assessments of BMD. In the cross-sectional study, cases with osteoporosis at the hip or lumbar vertebrae (T-score < or =-2.5) were matched to 3 controls with normal BMD (T-score > or =-1.0). In the longitudinal analysis, the change in BMD among PPI users and nonusers between successive BMD assessments was assessed. Conditional logistic regression and multivariate linear regression were used to obtain estimates of the association between PPI use and osteoporosis and of the annualized change in BMD associated with PPI use. PPI use was not associated with having osteoporosis at either the hip (OR, 0.84; 95% CI, 0.55-1.34) or the lumbar spine (OR, 0.79; 95% CI, 0.59-1.06) for PPI use >1500 doses over the previous 5 years. In the longitudinal study no significant decrease was observed in BMD at either site attributable to PPI use. PPI use does not appear to be associated with either the presence of osteoporosis or accelerated BMD loss. The association between PPI use and hip fracture is probably related to factors independent of osteoporosis.

(PDF emailed within 0-6 h: $19.90)

Accession: 055260844

Download citation: RISBibTeXText

PMID: 19931262

DOI: 10.1053/j.gastro.2009.11.014

Related references

Proton pump inhibitor omeprazole use is associated with low bone mineral density in maintenance haemodialysis patients. International Journal of Clinical Practice 63(2): 261-268, 2010

Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Archives of Internal Medicine 170(9): 765-771, 2010

Proton pump inhibitors use and change in bone mineral density. International Journal of Rheumatic Diseases 19(9): 864-868, 2016

Bone mineral density loss, osteoporosis, and fractures in HIV. Aids Reviews 15(3): 189-190, 2014

Fracture risk and bone mineral density reduction associated with proton pump inhibitors. PharmacoTherapy 32(1): 67-79, 2012

Correlation of Bone Mineral Density Scores and Proton Pump Inhibitors Use in the Elderly. Current Rheumatology Reviews 12(2): 162-166, 2015

Effect of long-term proton pump inhibitors on bone mineral density. La Tunisie Medicale 96(3): 193-197, 2018

Bone mineral density in lung-transplant recipients before and after graft: Prevention of lumbar spine posttransplantation-accelerated bone loss by pamidronate. Journal of Heart & Lung Transplantation 19(8): 736-743, August, 2000

Age-related bone mineral density, bone loss rate, prevalence of osteoporosis, and reference database of women at multiple centers in China. Journal of Clinical Densitometry 10(3): 276-284, 2007

Age-related bone mineral density, accumulated bone loss rate and prevalence of osteoporosis at multiple skeletal sites in chinese women. Osteoporosis International 13(8): 669-676, 2002

Osteoporosis and Bone Density Studies: Does treatment help decrease mineral loss?. Canadian Family Physician Medecin de Famille Canadien 38: 2139-2174, 1992

Accelerated metacarpal bone mineral density loss is associated with radiographic progressive hand osteoarthritis. Annals of the Rheumatic Diseases 70(9): 1625-1630, 2011

Proton pump inhibitors do not induce change in bone mineral density in a long-term observational study. Evidence-Based Medicine 18(5): 192-193, 2014

Efficacy of alfacalcidol and alendronate on lumbar bone mineral density in osteoporotic patients using proton pump inhibitors. Biomedical Reports 5(2): 165-170, 2016

Effects of Proton Pump Inhibitor Administration and Intake of a Combination of Yogurt and Galactooligosaccharides on Bone and Mineral Metabolism in Rats. Nutrients 8(10): -, 2016